Compare Adaptive Biotechnologies Corp (ADPT) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares MSCI India ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.14 (market cap $4.04B), while iShares MSCI India ETF trades at $49.95. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | INDA | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $25.45 | $55.29 |
52-Week Low | $12.30 | $45.42 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
INDA trades at $50.04, down 0.2% with a bullish technical signal from moving averages. The ETF reflects India's economic growth at 7.8% (CNBC, 2026-06-05) but faces headwinds from foreign outflows and sector-specific challenges in pharma and IT. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX indicates strong trend strength.
Outlook remains cautiously optimistic given India's strong economic fundamentals, though near-term risks include geopolitical tensions, monsoon uncertainties, and foreign capital rotation away from emerging markets. The ETF offers exposure to the world's fastest-growing large economy but requires monitoring of external pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
